Fig. 1

Disease course in mice treated with anti-mCD52 antibody in the acute or chronic stage of EAE. MP4-immunized mice were treated with 200 μg anti-mCD52 antibody or IgG2a isotype control for five consecutive days (tx) either a at the peak of the disease or b at ~ 60 days after EAE onset. c, d Representative disease course of individual animals treated during c acute or d chronic EAE. Arrows indicate the treatment period. e, f Flow cytometry of CD4⁺ T cells and CD19⁺ B cells in the blood after treatment with anti-mCD52 compared to vehicle. ***p < 0.001, Mann-Whitney test. Mean values ± SEM are shown. For EAE scores, statistics were calculated based on differences on a daily basis